Navigation Links
Golub Capital Provides Financing to Support The Recapitalization of Integrated DNA Technologies, Inc.
Date:4/23/2010

nd CEO.  "The financing provided by Golub Capital will help ensure that IDT maintains a strong balance sheet and has the flexibility necessary to pursue our ambitious plans for the future."

About Golub Capital

With $4 billion in capital, Golub Capital is a leading provider of financing solutions for the middle market, including one-loan financings (through the firm's proprietary GOLD facility), senior, second lien and subordinated debt, preferred stock and co-investment equity. The firm also underwrites and syndicates senior credit facilities up to $200 million. Golub Capital's hold sizes range from $10 million to $75 million per transaction.  Golub Capital was ranked by Thomson Reuters Loan Pricing Corporation as the #1 Traditional Middle Market Bookrunner for 2009.  For two years in a row, Golub Capital was named "Middle Market Lender of the Year" by Buyouts Magazine for achievements in 2009 and 2008.  Other honors awarded to Golub Capital include being named "2009 Mezzanine Financing Agent of the Year" and "2008 Financing Firm of the Year" by M&A Advisor and "2008 M&A Lender of the Year" by ACG's Mergers & Acquisitions. Golub Capital is a national firm with offices in Chicago, New York and Atlanta. For more information, please visit the firm's website at www.golubcapital.com.

Golub Capital Incorporated (and its various affiliates) creates and manages multiple private funds.  One of its affiliates, GC
'/>"/>

SOURCE Golub Capital
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Golub Capital Provides Debt Financing to Support the Acquisition of DNA Diagnostics Center, Inc. by MTS Health Investors, LLC
2. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
3. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
4. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
5. AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
6. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
7. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
8. CryoLife to Present at Bear Stearns Healthcare and First Albany Capitals Regenerative Technologies Conferences in New York
9. Luminex Corporation to Present at Americas Growth Capital Emerging Growth Conference
10. Altheus Therapeutics Secures $3.6 Million in Venture Capital
11. XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 SynGen Inc., a company that ... that harvest stem and progenitor cells from umbilical cord ... today that it has added three new members to ... Blood Business Units focus on product commercialization. ... its Vice President and Chief Financial Officer.  Chuck was ...
(Date:4/27/2015)... 2015  Haemonetics Corporation (NYSE: HAE ) ... 2015 of $226.5 million, down 6%.  Excluding currency ... The Company reported a fourth quarter GAAP net ... Adjusted net income, exclusive of transformation, restructuring and ... up 1%, and adjusted earnings per share were ...
(Date:4/27/2015)... and HEIDELBERG , ... Addresses unmet need in treatment of millions ... it has been granted a patent in ... latest patent supports Molecular Health,s discovery that EPHB4 is a ... and promotes tumor growth. EPO stimulates the production of red ...
(Date:4/27/2015)... DryLet, LLC a biotechnology company ... as animal waste reduction, bioremediation, wastewater treatment, aquaculture ... treatment plants and restaurant kitchen settings, announced today ... Commission on Environmental Quality (TCEQ) Environmental Trade Fair ... The company will highlight three of its key ...
Breaking Biology Technology:SynGen Inc. Expands Its Management Team 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 3Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 4Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 7Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 8Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 9Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 10Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 11Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 12Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 13Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 14Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 15Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 16Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 17Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 18Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 19Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 20Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 21Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 22Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 23Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 24Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 25Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 26Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 27Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 28Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 29Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 30Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 31Molecular Health Gains Patent for Novel Receptor Utilizing Computational Biomarker Discovery Technology 2DryLet to Showcase Multiple Products at Texas Commission on Environmental Quality Trade Fair and Conference May 5-6 in Austin, Texas 2
... 500 attendees are,already slated to attend Pharma ChemOutsourcing ... conference & exhibition continues to attract large numbers ... plus increasingly,dozens of mid-sized and smaller biotech companies. ... , Dr. Stefan Loren of Perceptive Life ...
... DSM Biologics and MorphoSys,AG (Frankfurt Stock Exchange: ... signing of a Biopharmaceutical Manufacturing Agreement,covering process ... is a,fully human HuCAL(R) antibody, directed against ... multiple myeloma. DSM Biologics will manufacture,MOR202 in ...
... August 12, - Major Threat Treatable With ... Models, An internationally renowned avian influenza expert ... by his,research team. This study demonstrated impressive efficacy ... and prevention of,H5N1, H1N1 and H3N2 in a ...
Cached Biology Technology:Stunning Attendance for ChemOutsourcing Show on September 8-9 in Long Branch, NJ 2DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody 2DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody 3Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic 2Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic 3Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic 4
(Date:4/21/2015)... , April 21, 2015 ... evolving government policies are boosting access control systems market ... According to a recently published report by TechSci ... 2020 ", the access control systems market in ... USD1.2 billion by 2020.The access control systems market in ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/20/2015)... -- The announcement comes as demand for ... (GRM), Ireland,s foremost records management company, ... up an impressive track record of clients within the first ... records management sector in Dubai . As ... and employ a further eight staff members at its Irish ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... specific types and conditions of dung has been given substantial ... dung from exotic mammals found on game farms or rewilding ... : Scarabaeidae ) Attraction to Native and Exotic Mammal ... Environmental Entomology , Sean D. Whipple, a postdoctoral research associate ...
... that lived within Arctic latitudes approximately 70 million years ... migrating to more southern latitudes, a recent study by ... Nature and Science in Dallas and Temple University has ... Perennial Polar Residents," in the April issue of the ...
... /PRNewswire-iReach/ -- Global Information Inc. is pleased ... research reports from Global Industry Analysts, available immediately, which ... reagents, and electrophoresis equipment and supplies markets coming out ... Technology: A Global Strategic Business Report ...
Cached Biology News:Exotic manure is sure to lure the dung connoisseur 2Duck-billed dinosaurs endured long, dark polar winters 2Duck-billed dinosaurs endured long, dark polar winters 3New Biotech and Pharmaceutical Market Research from Global Information Inc Forecasts Strong Growth Coming Out of Recession 2New Biotech and Pharmaceutical Market Research from Global Information Inc Forecasts Strong Growth Coming Out of Recession 3New Biotech and Pharmaceutical Market Research from Global Information Inc Forecasts Strong Growth Coming Out of Recession 4
... The micro 1 is a dramatic breakthrough in ... 1mL with 10nL resolution, the micro 1 has ... dispenser. And, the micro 1 never needs re-calibration ... Touch Screen programming on an LCD Display , ...
... series embodies all aspects of classical microscopy ... powerful Achromatic Super Contrast (ASC) objectives coupled ... this microscope combines flexibility and professional microscopy ... B1 series, the DM-B1 steps into the ...
... to Rad51 ( Abpromise for ... Antigen: Synthetic peptide: VEEESFGPQPISRLE conjugated ... amino acids 15-29 of Human Rad51 ... 5888 Swiss ...
... Dye Primer Manual Cycle Sequencing Kit is ... primers and high-resolution fluorescence scanners. Sequencing reactions ... slab gel electrophoresis and scanning of the ... The kit components have been optimized ...
Biology Products: